Claims
- 1. A method for the medical treatment of diabetes mellitus type II and for counteracting the risk factors forming part of the Metabolic syndrome (also known as "the deadly quartet" or "syndrome X" or the Insulin Resistance Syndrome) in a patient having increased cortisol activity, which method of treatment comprises decreasing said increased cortisol activity in said patient by the steps of providing an inhibitor of cortisol synthesis and administering an effective amount of said inhibitor to said patient in need thereof.
- 2. The method according to claim 1 wherein said inhibitor is a compound or mixture of compounds selected from the group consisting of:
- ketoconazole; and
- derivatives thereof having a corresponding biological activity as compared to ketoconazole.
- 3. A method for the medical treatment of diabetes mellitus type II and for counteracting the risk factors forming part of the Metabolic Syndrome (also known as "the deadly quartet" or "syndrome X" or the Insulin Resistance Syndrome) in a patient having increased cortisol activity, which method of treatment comprises decreasing said increased cortisol activity in said patient by the steps of: providing an inhibitor of cortisol synthesis; providing testosterone; and co-administering to said patient in need thereof: an amount of said inhibitor effective to decrease the increased cortisol activity in said patient; and an amount of testosterone effective to normalize any decrease in said patient's testosterone cause by said administration of said inhibitor.
- 4. The method according to claim 1, wherein the daily dose of the inhibitor is between 100 and 800 mg.
- 5. The method according to claim 2, wherein the daily dose of the inhibitor is between 100 and 800 mg.
- 6. The method according to claim 4 wherein 400 mg. of said inhibitor is administered to the patient in the evening.
- 7. The method according to claim 5 wherein 400 mg. of said inhibitor is administered to the patient in the evening.
- 8. A method for treating insulin insensitivity in a patient having increased cortisol activity, which method comprises decreasing the increased cortisol activity in said patient by the steps of providing an inhibitor of cortisol synthesis; and administering an amount of said inhibitor effective to decrease the increased cortisol activity to said patient in need thereof.
- 9. The method according to claim 8 wherein said inhibitor is ketoconazole, or derivatives thereof having a corresponding biological activity as compared to ketoconazole, or a mixture of both.
- 10. The method according to claim 8 wherein the daily dose of said inhibitor is between 100 and 800 mg.
- 11. The method according claim 10 wherein 400 mg. of said inhibitor is administered to the patent in the evening.
- 12. The method according to claim 8 wherein the patient is suffering from diabetes mellitus type II with insulin insensitivity.
- 13. A method of treating insulin insensitivity in a patient having increased cortisol activity, which method comprises decreasing the activity of cortisol in said patient by the steps of: providing an inhibitor of cortisol synthesis; providing testosterone; and co-administering to said patient in need thereof: an amount of said inhibitor effective to decrease said increased activity of cortisol in said patient; and an amount of said testosterone effective to normalize any decrease in said patient's testosterone caused by said administeration of said inhibitor.
- 14. The method according to claim 3, wherein the dose of the inhibitor is between 100 and 800 mg daily.
- 15. The method according to claim 3, wherein 400 mg of the inhibitor is administered to said patient in the evening.
- 16. The method according to claim 3, wherein the inhibitor is ketoconazole.
- 17. The method according to claim 13, wherein the dose of the inhibitor is between 100 and 800 mg daily.
- 18. The method according to claim 13, wherein 400 mg of the inhibitor is administered to said patient in the evening.
- 19. The method according to claim 13, wherein the inhibitor is ketoconazole.
Parent Case Info
This application is a continuation of Ser. No. 08/776,983 filed Feb. 6, 1997 now U.S. Pat. No. 5,849,740 and is a continuation of PCT/SE94/00729 filed Aug. 9, 1994.
US Referenced Citations (4)
Non-Patent Literature Citations (2)
Entry |
Viscera Obesity; A "Civilization Syndrome". Obesity Rsearch, vol. 1 No. 3, May 1993. |
A.T. Sapse, "Stress, Cortisol, Intreferon and `Stress` Diseases --I. Cortisol as the Cause of `Stress` Diseases", Medical Hypotheses, vol. 13 pp. 31-44,1984. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
776983 |
|
|